华纳药厂(688799) - 华纳药厂投资者关系活动记录表（2024年1月30日）

Group 1: Company Overview - Warner Pharmaceuticals reported a stable growth in business performance, with a revenue of CNY 1.056 billion in the first three quarters of 2023, representing a year-on-year increase of 13.89% [2] - The net profit attributable to shareholders reached CNY 158 million, up by 27.49% year-on-year, while the net profit excluding non-recurring gains and losses was CNY 149 million, reflecting a growth of 38.71% [2] Group 2: Product Performance - The revenue from formulation products was CNY 811 million, while the revenue from raw materials and intermediates was CNY 220 million [2] - The company has successfully bid for national centralized procurement for four products, including Montmorillonite Powder and PEG 4000 Powder, and has secured multiple regional procurement agreements for other products [2] Group 3: New Product Developments - Faropenem Sodium Granules, a unique formulation by the company, has been included in the National Basic Medical Insurance Directory for 2023, targeting infections caused by various bacteria [3] - The company’s Docusate Sodium Tablets are the only formulation of their kind in China, used for treating chronic functional constipation [3] - Bromovirin Tablets, approved in April 2023, are designed for early treatment of acute herpes zoster in immunocompetent adults [4] Group 4: Research and Development Initiatives - The company is collaborating with Hunan Tianji Rare Chinese Medicinal Materials Development Co., Ltd. and the Chinese Academy of Medical Sciences on research projects for artificial substitutes for rare and endangered animal medicinal materials [4] - The ZY022 project has completed preclinical research and is progressing to the next phase of development [4] Group 5: Sales and Marketing Strategy - The company has established a comprehensive marketing system for both formulation products and raw materials, with over 100 sales personnel as of the end of 2022 [5] - The focus is on enhancing professional service capabilities at market endpoints to effectively meet product demand [5]